Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Hepatocellular carcinoma is the most common type of malignant tumour in Asia. Treatment
is decided according to the staging system with information on tumour burden and liver …

Many guidelines for hepatocellular carcinoma (HCC) have been published and updated
globally. In contrast to other cancers, there is a range of treatment options for HCC involving …

Transarterial chemoembolization (TACE) is considered the gold standard for treating
intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC …

This study was undertaken to present data from a phase 2 study in which patients with
unresectable hepatocellular carcinoma (HCC) with and without portal vein thrombosis …

Hepatocellular carcinoma (HCC), the fifth most common cancer that predominantly occurs in
liver cirrhosis patients, requires staging systems to design treatments. The barcelona clinic …

Background For patients with hepatocellular carcinoma (HCC) with portal vein tumor
thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) …

Purpose To determine the efficacy and safety of transarterial chemoembolization (TACE) in
patients with hepatocellular carcinoma (HCC) and main portal vein (MPV) invasion …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Objective This article reviews the current results of various locoregional therapies for
hepatocellular carcinoma (HCC), with special reference to the implications for surgeons …